Gkb Ophthalmics Limited

As of June 30, 2026, Gkb Ophthalmics Limited carries a market capitalization of 317.56M, placing it among publicly traded companies globally. Its enterprise value stands at 317.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gkb Ophthalmics Limited has 5.04M shares outstanding.

As of June 30, 2026, Gkb Ophthalmics Limited trades at a trailing price-to-earnings ratio of 9.81.

As of June 30, 2026, Gkb Ophthalmics Limited trades at an EV/EBITDA multiple of 3.64 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.78 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 317.56M versus a market cap of 317.56M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 9.19M in revenue per employee across its workforce of 163.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gkb Ophthalmics Limited recorded 1.97M in income tax expense. That works out to an effective tax rate of 3.45, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 57.11M, leaving 32.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Gkb Ophthalmics Limited's stock has declined approximately 13.44% over the past 52 weeks. The 50-day moving average sits at 63.00, while the 200-day moving average is 60.48.

Over the twelve months ended June 30, 2026, Gkb Ophthalmics Limited generated 1.50B in revenue and converted that into 32.44M in net income, yielding earnings per share of 10.92. EBITDA reached 87.30M, while operating income came in at 69.85M.

Over the twelve months ended June 30, 2026, Gkb Ophthalmics Limited posted a gross margin of 29.13, reflecting its pricing power and cost economics. The operating margin of 4.66 and net profit margin of 2.17 provide insight into operational efficiency.